Anti-receptor Advanced Glycation End Products Decreases Inflammatory Pathways in Retinopathy Diabetics: In vivo Study

Authors

  • Ramzi Amin Department of Ophthalmology, Faculty of Medicine, Universitas Sriwijaya, Palembang, Indonesia
  • A. K. Ansyori Department of Ophthalmology, Faculty of Medicine, Universitas Sriwijaya, Palembang, Indonesia
  • Riani Erna Department of Ophthalmology, Faculty of Medicine, Universitas Sriwijaya, Palembang, Indonesia
  • Lilianty Fauzi Department of Ophthalmology, Faculty of Medicine, Universitas Sriwijaya, Palembang, Indonesia

DOI:

https://doi.org/10.3889/oamjms.2020.4293

Keywords:

Anti Receptor Advanced Glycation End Products, diabetic retinopathy, Diabetes mellitus, Inflammation

Abstract

BACKGROUND: Diabetic retinopathy is an emerging microvascular complication of diabetes mellitus and a causes of blindness in individuals between ages 30 and 70 years, which is characterized by increased proliferation of blood vessels, vascular occlusion, angiogenesis, loss of pericytes from retinal capillaries, microaneurysms, retinal bleeding, increased retinal capillary permeability, thickening of capillary basal membranes, and infarcts that affect the retina, induced to permanent blindness.

AIM: This study aimed to find the role of receptor advanced glycation end products (RAGE) inhibition in lowering the vascularization process which causes a decrease in retinal function on diabetic retinopathy.

MATERIALS AND METHODS: This research was an in vivo experimental study. A total of 30 male Wistar rats (200 ± 20 g) were obtained from Eureka Research Laboratory (Palembang, Indonesia). Experimental animals were placed in cages under controlled conditions (12 h of light/dark cycles with temperatures of 22 ± 1°C and humidity of 40–60%), fed and drank ad libitum. White rats were induced by diabetes mellitus using alloxan at a dose of 120 mg/kgBW, intraperitoneally, accompanied by drinking 10% glucose solution for 140 days. Furthermore, experimental animals were grouped into five groups (at eight animals per group), Group 1: Normal control, Group 2: Negative control (induced diabetics retinopathy and given intravenous aquadest), Group 3: Given anti-RAGE 1 ng/mL, Group 4: Given anti-RAGE 10 ng/mL, and Group 5: Given anti-RAGE 100 ng/mL. Giving anti-RAGE was done in a single dosage and intravitreal. After the rats were sacrificed by intraperitoneal injection of 10% chloral hydrate, the evacuation of the eye’s retinal tissue was then carried out, fixed in a 4% paraformaldehyde buffer for immunohistochemistry examination of the eye’s retinal tissue. Evaluation of the expression of nuclear factor-κβ (NF-kB) and intercellular adhesion molecule-1 (ICAM-1) used Image J Software so that the percentage of NF-kB and ICAM-1 expression would be obtained.

RESULTS: Negative control group showed an increase in NF-kB expression in the retinal tissue of diabetic retinopathy rats. Administration of anti-RAGE showed its potential to suppress NF-kB expression in retinal tissue of diabetic retinopathy white rats as well with an increase of anti-RAGE dose from 1 ng/mL to 100 ng/mL. Activation of NF-kB causes activation of the inflammatory cascade, which is characterized by the production of pro-inflammatory cytokines, one of which is ICAM-1. Giving anti-RAGE could suppress the expression of ICAM-1 along with an increase in anti-RAGE dose.

CONCLUSION: Anti-RAGE is able to block the inflammatory process, by inhibiting the expression of NF-kB and ICAM-1 in the retinal tissue of diabetics retinopathy in white rats.

Downloads

Download data is not yet available.

Metrics

Metrics Loading ...

Plum Analytics Artifact Widget Block

References

Xu J, Chen LJ, Yu J, Wang HJ, Zhang F, Liu Q, et al. Involvement of advanced glycation end products in the pathogenesis of diabetic retinopathy. Cell Physiol Biochem. 2018;48(2):705-17. https://doi.org/10.1159/000491897

Mathebula SD. Biochemical changes in diabetic retinopathy triggered by hyperglycaemia: A review. Afr Vision Eye Health. 2018;77(1):a439. https://doi.org/10.4102/aveh.v77i1.439

Singh VP, Bali A, Singh N, Jaggi AS. Advanced glycation end products and diabetic complications. Korean J Physiol Pharmacol. 2014;18(1):1-14. https://doi.org/10.4196/ kjpp.2014.18.1.1 PMid:24634591

Gaonkar MB, Krishnanda P. Pathogenesis of diabetic retinopathy: Biochemical aspects and therapeutic approaches. Sch J Appl Med Sci. 2015;3(5B):1880-90.

McVicar CM, Ward M, Colhoun LM, Guduric-Fuchs J, Bierhaus A, Fleming T, et al. Role of the receptor for advanced glycation endproducts (RAGE) in retinal vasodegenerative pathology during diabetes in mice. Diabetology. 2015;58(5):1129-37. https://doi.org/10.1007/s00125-015-3523-x PMid:25687235

Li G, Tang J, Du Y, Lee CA, Kern TS. Beneficial effects of a novel RAGE inhibitor in early diabetic retinopathy and tactile allodynia. Mol Vis. 2011;17:3156-65. PMid:22171162

Tobon-Velasco JC, Cuevas E, Torres-Ramos MA. Receptor for AGEs (RAGE) as mediator of NF-kB pathway activation in neuroinflammation and oxidative stress. CNS Neurol Disord Drug Targets. 2014;13(9):1615-26. https://doi.org/10.2174/187 1527313666140806144831 PMid:25106630

Saleh I, Maritska Z, Parisa N, Hidayat R. Inhibition of receptor for advanced glycation end products as new promising strategy treatment in diabetic retinopathy. Open Access Maced J Med Sci. 2019;7(23):3921-4. https://doi.org/10.3889/oamjms.2019.759 PMid:32165929

Goh SY, Cooper MK. Clinical review: The role of advanced glycation end products in progression and complications of diabetes. J Clin Endocrinol Metab. 2008;93(4):1143-52. PMid:18182449

American Academy of Ophthalmology Retina, Vitreous Panel. Prefered Practice Pattern: Diabetic Retinopathy. San Francisco, CA: American Academy of Ophthalmology; 2016.

Haoshen S. Inflammation in the Pathogenesis of Diabetic Retinopathy, Wayne State University Dissertations, 1965; 2018.

Zhang W, Liu H, Al-Shabrawey M, Caldwell RW, Caldwell RB. Inflammation and diabetic retinal microvascular complications. J Cardiovasc Dis Res. 2011;2(2):96-103. https://doi. org/10.4103/0975-3583.83035 PMid:21814413

Rubsam A, Parikh S, Fort PE. Role of inflammation in diabetic retinopathy. Int J Mol Sci. 2018;19(4):942. https://doi. org/10.3390/ijms19040942 PMid:29565290

Abul QF, Khan MS, Safar A, Al-Ghamdi SB, Ahmad I. Understanding biochemical and molecular mechanism of complications of glycation and its management by herbal medicine. In: New Look to Phytomedicine. United States: Academic Press; 2019. p. 331-66. https://doi.org/10.1016/ b978-0-12-814619-4.00013-6

Mohammad G, Siddiquei MM, Othman A, Al-Shabrawey M, Abu El-Asrar AM. High-mobility group box-1 protein activates inflammatory signaling pathway components and disrupts retinal vascular-barrier in the diabetic retina. Exp Eye Res. 2013;107:101-9. https://doi.org/10.1016/j.exer.2012.12.009 PMid:23261684

Liu Y, Costa MB, Gerhardinger C. IL-1beta is upregulated in the diabetic retina and retinal vessels: Cell-specific effects of high glucose and IL-1beta autostimulation. PLoS One. 2012;7(5):e36949. https://doi.org/10.1371/journal.pone.0036949 PMid:22615852

Wang J, Li R, Deng Z, Sun Z, Chai L, Guo H, Wang, S. Xueshuantong for injection ameliorates diabetic nephropathy in a rat model of streptozotocin-induced diabetes. Chin J Physiol. 2018;61(6):349-59. PMid:30580505

Downloads

Published

2020-07-25

How to Cite

1.
Amin R, Ansyori AK, Erna R, Fauzi L. Anti-receptor Advanced Glycation End Products Decreases Inflammatory Pathways in Retinopathy Diabetics: In vivo Study. Open Access Maced J Med Sci [Internet]. 2020 Jul. 25 [cited 2024 Mar. 29];8(A):414-7. Available from: https://oamjms.eu/index.php/mjms/article/view/4293